As of Apr 17, 2018 Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Shorts Declined By 10.57%

April 17, 2018 - By Theresa Judd

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Corporate Logo

During 2017 Q4 the big money sentiment increased to 2.08. That’s change of 1.12, from 2017Q3’s 0.96. 10 investors sold all, 28 reduced holdings as Achillion Pharmaceuticals, Inc. ratio increased. 45 rose positions while 34 funds bought positions. Funds hold 110.36 million shares thus 4.96% more from 2017Q3’s 105.14 million shares.
Parallax Volatility Advisers Limited Partnership has invested 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Sg Americas Securities Ltd Liability Corporation, a New York-based fund reported 11,067 shs. Geode Cap Lc stated it has 1.05M shs. Blackrock holds 0% or 11.57M shs in its capital. Financial Bank Of America Corporation De holds 0% or 442,778 shs in its capital. Federated Pa holds 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 5,819 shs. D E Shaw stated it has 367,197 shs. Savings Bank Of Montreal Can stated it has 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Jpmorgan Chase And Co holds 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.16 million shs. Parametric Associates Limited Liability invested in 0% or 55,229 shs. Ubs Asset Mgmt Americas owns 64,639 shs for 0% of their capital. Royal National Bank Of Canada invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Renaissance Technology Limited Liability Corp reported 2.18M shs. Dimensional Fund Advsr Ltd Partnership reported 4.73M shs. Cubist Systematic Strategies Ltd Llc owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 17,692 shs.

Change of 10.57% for Achillion Pharmaceuticals Inc (NASDAQ:ACHN)’s shares shorted was showed. FINRA published shares shorted of ACHN’s total 9.23 million shares. Previously was reported down change of 10.57% from 10.32 million shares. Previous ACHN’s position will need 5 days to restore. It has 1.87M average volume. Float short on Achillion Pharmaceuticals Inc is 9.01%.

On during the last trading session the stock decreased $0.12 or 3.26%, reaching $3.56.Achillion Pharmaceuticals, Inc. has volume of 509,340 shares. Since April 17, 2017 ACHN has declined 2.57% and is downtrending. ACHN underperformed by 14.12% the S&P 500.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.The company has $490.90 million market cap. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial.Currently it has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Total analysts of 4 have positions in Achillion Pharmaceuticals (NASDAQ:ACHN) as follows: 1 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 25%. The firm has $5.0 highest while $3.5 is the lowest [Target]. The average target $4 is 12.36% above the last ($3.56) price. Since October 23, 2017 according to StockzIntelligence Inc Achillion Pharmaceuticals has 5 analyst reports. On Wednesday, February 7 the firm has “Hold” rating given by FBR Capital. In Monday, October 23 report Robert W. Baird maintained the stock with “Hold” rating. On Friday, February 23 the firm has “Hold” rating given by FBR Capital. On Monday, December 11 Leerink Swann maintained the shares of ACHN in report with “Buy” rating.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: